Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by SSRI Prescribers (US)

Analysis of: Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
This article clearly describes the Catch-22 in which most doctors, except for those employed by the large institutions, find themselves.  We cannot afford to practice the "best" medicine, and yet, if we could, we might well make fewer errors and make medical care for our patients more seamless. ...
June 16, 2008
exenatide
Analysis of: After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 (newsroom.lilly.com)
Once a week treatment for diabetes with no weight gain.
June 16, 2008
mab12
Analysis of: Investigational Anti-IgE Antibody Promising as Extracorporeal Allergy Therapy (www.medscape.com)
more prescribing habits of a more potent antibody. It also would be preferred for those patients whose IgE levels are too great fro treatment with Xolair.
Daniel Wynn, MD, Director, Clinical Research
Daniel Wynn, MD, Director, Clinical Research
Consultants In Neurology Ltd.
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis (www.asia-manufacturing.com)
Extavia, Novartis' brand of  interferon beta 1b, has been approved for the  treatment of multiple sclerosis by the European Union.  With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009.  While essentially identical to Bayer's Betaferon interferon beta 1b,...
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
Manipulation of the nicotinic receptor is a novel way to treat ADHD which has significant potential to modify the symptoms of this disorder and to enhance learning and memory.  We have had some difficulty with side effects of varenicline which is a nicotinic partial agonist used in smoking cessation...
Daniel Wynn, MD, Director, Clinical Research
Daniel Wynn, MD, Director, Clinical Research
Consultants In Neurology Ltd.
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD.  The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Louis Sanfilippo, MD, President
Louis Sanfilippo, MD, President
LCS Group, LLC
Analysis of: BrainCells Inc. Initiates Phase 2 Clinical Trial With BCI-540 For Depression With Anxiety (www.medicalnewstoday.com)
It’s not clear just how BrainCells’ BCI-540 works but the company claims the drug acts by way of promoting neurogenesis without an effect on serotonin neurotransmission.   While SSRI’s also promote neurogenesis, a downstream effect believed to favorably impact mood and anxiety, they obviously...
Analysis of: FDA Approves AstraZeneca’s Seroquel for Maintenance Treatment in Bipolar Disorder (www.astrazeneca.com)
Specific pharmacology Borad range of indications Validation of some current prescribing patterns Possible gradual increased use of the medication
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
This is a potentially interesting alternative to current ADHD stimulant treatment. There is, I believe, existing literature on the efficacy of nicotine patches in the treatment of severe,otherwise intractable ADHD in children, which would seem to support these results. Of course, much work remains to...
Analysis of: Johnson & Johnson Presents Tapentadol Phase 3 Clinical Data at American Pain Society's Annual Meeting (www.investor.jnj.com)
Don't bother listening to the May 6 audio presentation, as it is a useless waste of time.  Just look at the pdf slide presentation, showing tapentadol IR to provide equivalent pain control to 10 or 15mg oxycodone, with reduced GI side effects, in treating acute bunionectomy pain and also arthritis...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 572

Analytics


Generated at 2009-01-09T13:00:20.343